{"schema_version":"secwatch.filing_event.v1","accession":"0001297184-22-000060","form_type":"8-K","ticker":"AMPH","cik":"0001297184","company_name":"Amphastar Pharmaceuticals, Inc.","filed_at":"2022-11-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.044195+00:00","generated_at":"2026-06-21T15:41:48.006498+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Amphastar subsidiary enters up to $1.5M supply deal with related party Letop Biotech","bullets":["ANP subsidiary signed 3-year supply agreement with Nanjing Letop Biotechnology for chemical intermediates.","Total cost capped at ~$1.5M over 3 years; no minimum purchase obligation for ANP.","Henry Zhang, immediate family of CEO Jack Zhang and Chair Mary Luo, owns majority of Letop; deal was approved by independent Audit Committee members.","ANP retains ownership of all confidential information shared with Letop under the agreement.","Payments in Chinese yuan; price adjustments allowed once per 12 months with 2-month notice and customer consent."],"urls":{"canonical":"https://secwatch.observer/filing/0001297184-22-000060","json":"https://secwatch.observer/filing/0001297184-22-000060.json","markdown":"https://secwatch.observer/filing/0001297184-22-000060.md","text":"https://secwatch.observer/filing/0001297184-22-000060.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1297184/000129718422000060/0001297184-22-000060-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1297184/000129718422000060/amph-20221115x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T15:41:48.006498+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5c1f86b2a580fb988b7672985e91ae24f9517340","claim":"Amphastar Pharmaceuticals, Inc. entered into Agreement with Nanjing Letop Biotechnology Co., Ltd. valued at approximately $1.5 million (effective 2022-11-15).","evidence_excerpt":"On November 15, 2022 (the “Effective Date”) Amphastar Nanjing Pharmaceuticals, Inc. (“ANP”), a wholly owned subsidiary of Amphastar Pharmaceuticals, Inc. (the “Company”), entered into a supply agreement (the “Agreement”) with Nanjing Letop Biotechnology Co., Ltd. (“Letop”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1297184/000129718422000060/0001297184-22-000060-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"supply"},{"label":"Counterparty","value":"Nanjing Letop Biotechnology Co., Ltd."},{"label":"Value","value":"approximately $1.5 million"},{"label":"Effective","value":"2022-11-15"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}